Atopic Dermatitis Therapy Using MSC-Derived Extracellular Vesicles

EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

EXP01 is a first-in-class topical therapy using MSC-derived extracellular vesicles (“Prime-EV”) that both suppresses inflammation and rebuilds the skin barrier, aiming to shift AD care from “firefighting” to prevention for 200M+ patients worldwide.

In vivo, topical EV achieved a 78% improvement in total clinical score and outperformed a topical steroid; TEWL was restored close to baseline, supporting barrier repair.

Chronic dosing showed no weight loss or thymic atrophy.

The program is positioned as a long-term alternative to TCS/TCI in moderate AD, and as an add-on to biologics/JAK inhibitors in severe AD.

With patent-pending, a first-in-class barrier-rebuilding profile and low immunosuppression risk, Phase 1/2a initiation is planned for 2028.

Built on our Prime-EV platform with defined QC markers and advanced CMC, we are exploring co-development and regional out-licensing opportunities.